Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
VCYT

VCYT - Veracyte Inc Stock Price, Fair Value and News

23.18USD-0.75 (-3.13%)Market Closed

Market Summary

VCYT
USD23.18-0.75
Market Closed
-3.13%

VCYT Alerts

  • 2 major insider sales recently.

VCYT Stock Price

View Fullscreen

VCYT RSI Chart

VCYT Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-25.99

Price/Sales (Trailing)

4.72

EV/EBITDA

-35.26

Price/Free Cashflow

67.31

VCYT Price/Sales (Trailing)

VCYT Profitability

Operating Margin

90.39%

EBT Margin

-18.76%

Return on Equity

-6.09%

Return on Assets

-5.68%

Free Cashflow Yield

1.49%

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

375.5M

Rev. Growth (Yr)

17.5%

Rev. Growth (Qtr)

-1.38%

VCYT Earnings

Earnings (TTM)

-68.2M

Earnings Growth (Yr)

76.96%

Earnings Growth (Qtr)

93.41%

Breaking Down VCYT Revenue

Last 7 days

1.9%

Last 30 days

8.3%

Last 90 days

19.2%

Trailing 12 Months

-17.3%

How does VCYT drawdown profile look like?

VCYT Financial Health

Current Ratio

5

VCYT Investor Care

Shares Dilution (1Y)

5.57%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024375.5M000
2023311.2M328.6M343.1M361.1M
2022250.6M268.4M283.6M296.5M
2021123.1M157.5M186.7M219.5M
2020122.0M112.5M112.7M117.5M
2019101.5M108.9M116.4M120.4M
201875.6M79.9M85.9M92.0M
201768.0M71.7M70.6M72.0M
201651.8M54.6M60.9M65.1M
201541.9M45.2M47.7M49.5M
201425.0M28.6M32.8M38.2M
201314.5M17.1M19.5M21.9M
20124.9M7.1M9.4M11.6M
20110002.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Veracyte Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 16, 2024
holstein jens
sold
-122,500
24.5
-5,000
-
Jul 16, 2024
leite john
sold
-31,925
25.00
-1,277
chief commercial officer-clia
Jul 16, 2024
eastham karin
sold
-187,500
25.00
-7,500
-
Jun 13, 2024
epstein robert s
acquired
-
-
11,473
-
Jun 13, 2024
bhanji muna
acquired
-
-
11,473
-
Jun 13, 2024
holstein jens
acquired
-
-
11,473
-
Jun 13, 2024
eastham karin
acquired
-
-
11,473
-
Jun 13, 2024
barr eliav
acquired
-
-
11,473
-
Jun 13, 2024
jones evan/ fa
acquired
-
-
11,473
-
Jun 11, 2024
eastham karin
sold
-79,683
20.59
-3,870
-

1–10 of 50

Which funds bought or sold VCYT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
First Horizon Advisors, Inc.
reduced
-0.57
-1,822
63,904
-%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-4.95
-5,234,080
68,945,100
0.05%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
13.05
2,114
22,147
-%
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-37.82
-125,484
194,662
0.03%
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
17.00
347
-%
Jul 18, 2024
Signature Resources Capital Management, LLC
new
-
82,541
82,541
0.07%
Jul 18, 2024
Blue Trust, Inc.
added
2,331
29,451
30,714
-%
Jul 18, 2024
Asset Management One Co., Ltd.
added
54.00
51,097
152,080
-%
Jul 18, 2024
Assenagon Asset Management S.A.
unchanged
-
-6,342
280,475
-%
Jul 17, 2024
KBC Group NV
added
20.29
8,000
51,000
-%

1–10 of 48

Are Funds Buying or Selling VCYT?

Are funds buying VCYT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VCYT
No. of Funds

Unveiling Veracyte Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 08, 2024
blackrock inc.
10.2%
7,793,059
SC 13G/A
Feb 13, 2024
vanguard group inc
9.75%
7,118,211
SC 13G/A
Feb 12, 2024
artisan partners limited partnership
4.4%
3,217,728
SC 13G/A
Feb 08, 2024
wellington management group llp
9.68%
7,068,435
SC 13G/A
Jan 29, 2024
ark investment management llc
10.48%
7,655,603
SC 13G/A
Jan 24, 2024
blackrock inc.
9.8%
7,161,866
SC 13G/A
Jan 22, 2024
state street corp
4.26%
3,108,639
SC 13G/A
Jun 09, 2023
wellington management group llp
10.01%
7,248,889
SC 13G/A
Feb 10, 2023
invesco ltd.
0.4%
313,974
SC 13G/A
Feb 10, 2023
ark investment management llc
11.57%
8
SC 13G/A

Recent SEC filings of Veracyte Inc

View All Filings
Date Filed Form Type Document
Jul 18, 2024
4
Insider Trading
Jul 18, 2024
4
Insider Trading
Jul 18, 2024
4
Insider Trading
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 08, 2024
SC 13G/A
Major Ownership Report
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading

Peers (Alternatives to Veracyte Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Veracyte Inc News

Latest updates
Defense World30 hours ago
Yahoo Finance17 Jul 202408:48 am
MarketBeat16 Jul 202410:53 pm
American Banking and Market News12 Jul 202407:00 am

Veracyte Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-1.4%96,844,00098,199,00090,108,00090,322,00082,422,00080,297,00075,592,00072,864,00067,783,00067,336,00060,370,00055,105,00036,703,00034,536,00031,121,00020,704,00031,122,00029,730,00030,973,00030,136,00029,529,000
Cost Of Revenue------------------9,673,0009,114,0008,777,0008,513,000
Costs and Expenses-24.1%101,500,000133,706,000121,847,00098,373,00092,920,00085,717,00085,272,00083,597,00083,031,00079,669,00077,051,00062,579,00082,118,00042,608,00035,187,00031,755,00043,322,00037,927,00032,736,00033,236,00031,596,000
  S&GA Expenses-5.9%23,782,00025,260,00024,344,00025,756,00026,130,00024,127,00025,678,00024,001,00023,754,00022,212,00021,670,00019,662,00016,296,00013,149,00010,955,00010,701,00017,584,00014,183,00013,088,00013,943,00012,477,000
  R&D Expenses-14.5%15,965,00018,673,00013,322,00012,541,00012,769,00011,287,00010,773,0009,377,0009,166,00010,252,0008,006,0006,249,0005,336,0004,586,0004,042,0004,169,0004,407,0004,443,0003,643,0003,330,0003,435,000
EBITDA Margin13.8%-0.12-0.14-0.06-0.01-0.01-0.04-0.07-0.09-0.11-0.28-0.34-0.36---------
Interest Expenses------9,000-----27,00063,000--76,00055,00065,00055,000-264,00058,000235,000303,000
Income Taxes98.0%-44,000-2,179,000-154,000125,000-410,500-152,000-100,000-3,000-762,500-1,400,000-152,000-3,795,000--------
Earnings Before Taxes93.7%-1,908,000-30,472,000-29,772,000-8,277,000-8,091,000-3,441,000-8,875,000-9,647,000-14,464,000-11,317,000-15,479,000-9,190,000-45,663,000-8,044,000-4,124,000-11,025,000-11,716,000----
EBT Margin11.6%-0.19-0.21-0.14-0.09-0.10-0.12-0.16-0.19-0.20-0.37-0.42-0.43---------
Net Income93.4%-1,864,000-28,293,000-29,618,000-8,402,000-8,091,000-3,844,000-8,723,000-9,532,000-14,461,000-10,528,000-14,129,000-9,038,000-41,868,000-8,044,000-4,124,000-11,025,000-11,716,000-7,458,000-730,000-2,494,000-1,917,000
Net Income Margin11.9%-0.18-0.21-0.15-0.09-0.10-0.12-0.15-0.18-0.19-0.34-0.39-0.40---------
Free Cashflow-185.0%-11,100,00013,055,00011,369,00013,002,000-3,165,0007,872,0005,312,000-2,873,000-11,325,0007,605,000-3,205,000360,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets7.6%1,2001,1151,1251,1611,1571,1561,1261,1441,1741,1881,1861,0271,025457454257267275260252124
  Current Assets1.7%29028627125925224923923523824322937136237637017318118822822091.00
    Cash Equivalents-3.4%20921620219117915517115416417316532832535034614815416019619368.00
  Inventory13.6%18.0016.0016.0012.0013.0014.0014.0015.0012.0011.0010.007.006.005.004.007.006.007.007.005.004.00
  Net PPE------------12.0011.009.009.009.009.009.008.008.008.00
  Goodwill7.2%7547036936997006966776907047087144724753.003.003.003.003.001.001.00-
Liabilities15.0%81.0071.0071.0078.0076.0081.0078.0080.0088.0091.0079.0056.0051.0036.0031.0031.0037.0036.0029.0028.0040.00
  Current Liabilities-5.2%58.0061.0057.0058.0056.0063.0058.0059.0063.0064.0050.0036.0033.0017.0014.0013.0019.0017.0017.0015.0014.00
  Long Term Debt-----------1.001.001.001.001.001.001.001.001.001.0013.00
    LT Debt, Current-------1.001.001.001.00-----------
    LT Debt, Non Current-----------1.001.001.001.001.001.001.001.001.001.0013.00
Shareholder's Equity7.1%1,1191,0441,0541,0831,0811,0751,0481,0641,0851,0971,10797197442142322623023923122484.00
  Retained Earnings-0.4%-469-468-439-410-401-393-389-381-371-357-346-332-323-281-273-269-258-246-239-238-236
  Additional Paid-In Capital5.3%1,6171,5361,5281,5211,5101,5001,4921,4831,4771,4691,4621,3041,298703696496489486470463320
Shares Outstanding4.3%76.0073.0073.0073.0072.0072.0071.0071.0071.0068.0070.0065.00---------
Float----1,700---1,400---2,700---1,300---1,300-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-157.7%-8,96615,55214,17116,671-2,1729,7447,026-363-8,8728,446-1,3931,887-40,5612,2611,752-8,423-5,3011,790-1,556-2,455-1,011
  Share Based Compensation6.7%8,0197,5127,26310,3817,9856,8677,2835,9396,6456,7327,8684,0643,8553,6413,0893,3602,9052,8422,6402,5661,759
Cashflow From Investing215.3%2,878-2,497-2,802-3,66924,080-26,4348,807-9,307-2,453385-165,4571,473-575,607-888-1,635-649-665-41,100-226-658-749
Cashflow From Financing-234.0%-8646451103971,68593.001,486-75.001,9901733,2151,920591,0122,911197,5133,390-2192,9654,797127,919-8,394
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VCYT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 96,844,000$ 82,422,000
Operating expenses:  
Research and development15,965,00012,769,000
Selling and marketing23,782,00026,130,000
General and administrative26,210,00021,053,000
Impairment of long-lived assets429,0001,410,000
Intangible asset amortization3,653,0005,329,000
Total operating expenses101,500,00092,920,000
Loss from operations(4,656,000)(10,498,000)
Other income, net2,748,0002,407,000
Loss before income taxes(1,908,000)(8,091,000)
Income tax benefit(44,000)0
Net loss$ (1,864,000)$ (8,091,000)
Net loss per common share, basic (in USD per share)$ (0.02)$ (0.11)
Net loss per common share, diluted (in USD per share)$ (0.02)$ (0.11)
Shares used to compute net loss per common share, basic (in shares)74,759,78972,175,457
Shares used to compute net loss per common share, diluted (in shares)74,759,78972,175,457
Testing revenue  
Revenue:  
Total revenue$ 90,303,000$ 72,396,000
Operating expenses:  
Cost of revenue25,979,00019,648,000
Product revenue  
Revenue:  
Total revenue3,537,0003,892,000
Operating expenses:  
Cost of revenue2,644,0002,162,000
Biopharmaceutical and other revenue  
Revenue:  
Total revenue3,004,0006,134,000
Operating expenses:  
Cost of revenue$ 2,838,000$ 4,419,000

VCYT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 209,188$ 216,454
Accounts receivable46,66540,378
Supplies and inventory18,32816,128
Prepaid expenses and other current assets16,23712,661
Total current assets290,418285,621
Property, plant and equipment, net21,56620,584
Right-of-use assets, operating leases11,16710,277
Intangible assets, net116,34888,593
Goodwill753,853702,984
Restricted cash1,082876
Other assets5,6395,971
Total assets1,200,0731,114,906
Current liabilities:  
Accounts payable12,15212,943
Accrued liabilities30,29338,427
Current portion of deferred revenue2,6022,008
Current portion of acquisition-related contingent consideration6,9342,657
Current portion of operating lease liabilities5,9825,105
Current portion of other liabilities89101
Total current liabilities58,05261,241
Deferred tax liabilities1,340734
Acquisition-related contingent consideration, net of current portion13,446518
Operating lease liabilities, net of current portion8,0587,525
Other liabilities528786
Total liabilities81,42470,804
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 125,000,000 shares authorized, 76,425,272 and 73,264,738 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively7673
Additional paid-in capital1,617,4651,536,168
Accumulated deficit(469,985)(468,121)
Accumulated other comprehensive loss(28,907)(24,018)
Total stockholders’ equity1,118,6491,044,102
Total liabilities and stockholders’ equity$ 1,200,073$ 1,114,906
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEveracyte.com
 INDUSTRYBiotechnology
 EMPLOYEES787

Veracyte Inc Frequently Asked Questions


What is the ticker symbol for Veracyte Inc? What does VCYT stand for in stocks?

VCYT is the stock ticker symbol of Veracyte Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veracyte Inc (VCYT)?

As of Fri Jul 19 2024, market cap of Veracyte Inc is 1.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers. The fair value of Veracyte Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Veracyte Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VCYT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Veracyte Inc a good stock to buy?

The fair value guage provides a quick view whether VCYT is over valued or under valued. Whether Veracyte Inc is cheap or expensive depends on the assumptions which impact Veracyte Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCYT.

What is Veracyte Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, VCYT's PE ratio (Price to Earnings) is -25.99 and Price to Sales (PS) ratio is 4.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCYT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veracyte Inc's stock?

In the past 10 years, Veracyte Inc has provided 0.05 (multiply by 100 for percentage) rate of return.